Daewoong Pharmaceutical and T-On Lab Win Domestic Phase 1 Approval for Once-Monthly Obesity Treatment
Published
Daewoong Pharmaceutical and T-On Lab have received domestic Phase 1 clinical trial approval for an obesity treatment that is given once a month. Phase 1 is the first stage in which a new drug is tested in people. It is mainly carried out to check the drug's safety and how it works in the body.
Alongside this news, the patent situation in South Korea's pharmaceutical industry was also reported. According to the report, the company with the most valid patents was Novartis Korea, with 69. Roche Korea followed with 66, and Hanmi Pharmaceutical took third place with 52. Sanofi-Aventis and other companies also appeared in the rankings.
A patent is a legal right that protects a technology or product developed by a company. In the pharmaceutical industry, the number of patents a company holds is often used as one indicator of its research ability.
However, the report does not give detailed information about the schedule, participants or future plans for this Phase 1 trial. More details are expected to be made public through further announcements from the companies involved.
Sources: 헬스코리아뉴스
More South Korea news
- US Air Taxi Company Joby Posts Higher Third-Quarter Revenue on Growth of Subsidiary's Passenger Business
- CJ Olive Young Aims to Become a "Global Tech Platform" Led by AI
- Smart farming company GreenFarm to enter domestic and overseas markets in partnership with Korea Agricultural Development Institute
- Alchera's Subsidiary YouSeeB to Take Part in Korea Fintech Week 2026
- How Will China's Manufacturing Growth Affect South Korea's Future?
- South Korea Ranks First in UN E-Government Survey for the First Time in 12 Years
- President Lee's approval rating at 40%; Democratic Party 36%, People Power Party 28%, ruling party leads
- Presidential Secretary Im Kwang-hyun Visits the National Council of Churches in Korea, Continuing Dialogue with Religious Groups